Viatris Inc.(VTRS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VTRS Viatris Inc.

盘后交易 03-25 17:42:54 EDT

13.50

+0.14

+1.05%

盘后13.51

+0.01+0.07%

17:40 EDT

最高13.69	最低13.47	成交量575.00万
今开13.48	昨收13.36	日振幅1.65%
总市值155.49亿	流通市值155.49亿	总股本11.52亿
成交额7,790万	换手率0.50%	流通股本11.52亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VTRS","market":"US","secType":"STK","nameCN":"Viatris Inc.","latestPrice":13.5,"timestamp":1774468800000,"preClose":13.36,"halted":0,"volume":5750000,"hourTrading":{"tag":"盘后","latestPrice":13.51,"preClose":13.5,"latestTime":"17:40 EDT","volume":204425,"amount":2759740.9752249997,"timestamp":1774474826271,"change":0.01,"changeRate":0.000741,"amplitude":0.01037},"delay":0,"changeRate":0.010479041916167707,"floatShares":1151769872,"shares":1151769872,"eps":-3.002391,"marketStatus":"盘后交易","change":0.14,"latestTime":"03-25 17:42:54 EDT","open":13.48,"high":13.69,"low":13.47,"amount":77895577.75,"amplitude":0.016467,"askPrice":14,"askSize":2,"bidPrice":13.4,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.002391,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1774483200000},"marketStatusCode":4,"adr":0,"listingDate":1605157200000,"exchange":"NASDAQ","adjPreClose":13.36,"dividendRate":0.035556,"preHourTrading":{"tag":"盘前","latestPrice":13.48,"preClose":13.36,"latestTime":"09:29 EDT","volume":829,"amount":11130.027992,"timestamp":1774445399999,"change":0.12,"changeRate":0.008982,"amplitude":0.008234},"postHourTrading":{"tag":"盘后","latestPrice":13.51,"preClose":13.5,"latestTime":"17:40 EDT","volume":204425,"amount":2759740.9752249997,"timestamp":1774474826271,"change":0.01,"changeRate":0.000741,"amplitude":0.01037},"volumeRatio":0.464155,"impliedVol":0.4314,"impliedVolPercentile":0.7092},"requestUrl":"/m/hq/s/VTRS","defaultTab":"news","newsList":[{"id":"1164782158","title":"Viatris在日本获批Effexor®用于成人广泛性焦虑症治疗 创新产品组合再获突破","url":"https://stock-news.laohu8.com/highlight/detail?id=1164782158","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164782158?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:00","pubTimestamp":1774263618,"startTime":"0","endTime":"0","summary":"Viatris Inc.宣布其抗焦虑药物Effexor®正式获得日本监管机构批准，适用于成人广泛性焦虑症（GAD）的治疗。此次获批标志着该公司创新产品组合的战略推进取得重要进展。\n该药物在日本市场的准入将为企业拓展神经精神疾病治疗领域提供新的增长动能，同时强化Viatris在亚太地区专科药物市场的布局。此次获批也体现了公司持续通过引入差异化治疗方案来满足临床未竟需求的承诺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","LU1839511570.USD","BK4007","BK4588","BK4585","LU2087621335.USD","VTRS"],"gpt_icon":0},{"id":"1132079552","title":"Viatris展望2030年：调整后每股收益复合年增长率预计达9%-10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1132079552","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132079552?lang=zh_cn&edition=full","pubTime":"2026-03-19 20:59","pubTimestamp":1773925159,"startTime":"0","endTime":"0","summary":"Viatris Inc.近日发布长期业绩指引，预计到2030年，公司调整后每股收益的复合年增长率将维持在9%至10%的区间。这一预测展现了管理层对未来盈利能力的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4585","LU2087621335.USD","BK4583","LU1839511570.USD","BK4588","VTRS"],"gpt_icon":0},{"id":"1132408834","title":"GoodRx Holdings, Inc.：现金支付消费者可在全美逾7万家药房享受最高85%折扣","url":"https://stock-news.laohu8.com/highlight/detail?id=1132408834","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132408834?lang=zh_cn&edition=full","pubTime":"2026-03-11 21:03","pubTimestamp":1773234207,"startTime":"0","endTime":"0","summary":"GoodRx Holdings, Inc. 宣布，通过其平台，使用现金支付的消费者可在全美超过70,000家药房享受高达85%的药品折扣。这一服务旨在帮助没有医疗保险或选择自费购药的人群降低医疗成本。\n目前，GoodRx已与多家大型药房连锁品牌合作，覆盖范围广泛。用户只需在购药时出示GoodRx提供的优惠码，即可直接享受价格减免。公司表示，此举将有效缓解部分民众的用药经济压力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4167","GDRX","VTRS","BK4585","LU1839511570.USD","BK4583","BK4588","LU2087621335.USD"],"gpt_icon":0},{"id":"1103779517","title":"Viatris首席执行官透露11月与FDA就印多尔工厂进展进行会谈，预计今年内准备就绪迎接复查但具体时间由FDA决定——电话会议信息","url":"https://stock-news.laohu8.com/highlight/detail?id=1103779517","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103779517?lang=zh_cn&edition=full","pubTime":"2026-02-26 21:47","pubTimestamp":1772113661,"startTime":"0","endTime":"0","summary":"Viatris Inc. 首席执行官在近期电话会议中透露，公司已于去年11月与美国食品药品监督管理局（FDA）会面，专题汇报印度印多尔工厂的整改进展。首席执行官明确表示，该工厂将在今年内全面准备就绪，以迎接FDA的再次现场检查，但具体复查时间安排仍取决于监管机构的日程规划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2087621335.USD","VTRS","BK4007","LU1839511570.USD","BK4588","BK4585","BK4583"],"gpt_icon":0},{"id":"1165038494","title":"Viatris公司预计重组活动及相关成本节约将在未来三年内基本完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1165038494","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165038494?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:27","pubTimestamp":1772108863,"startTime":"0","endTime":"0","summary":"Viatris公司表示，其当前推行的重组计划、相关的成本支出以及预期实现的节约效益，预计将主要在接下来的三年时间内完成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1839511570.USD","BK4583","VTRS","BK4585","BK4588","LU2087621335.USD"],"gpt_icon":0},{"id":"1147503203","title":"Viatris Inc.重组计划全面实施后，预计可节省6亿至7亿美元成本","url":"https://stock-news.laohu8.com/highlight/detail?id=1147503203","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147503203?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:26","pubTimestamp":1772108794,"startTime":"0","endTime":"0","summary":"Viatris Inc.宣布，其正在推进的重组活动一旦全面落地，有望为公司带来6亿至7亿美元的成本节约。这一举措旨在优化运营效率，提升长期盈利能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","VTRS","BK4007","LU2087621335.USD","LU1839511570.USD","BK4588","BK4585"],"gpt_icon":0},{"id":"1138093737","title":"异动解读 | Viatris Inc.宣布重组计划，预计产生高额费用，股价盘前大跌7.34%","url":"https://stock-news.laohu8.com/highlight/detail?id=1138093737","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138093737?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:24","pubTimestamp":1772108680,"startTime":"0","endTime":"0","summary":"Viatris Inc.（股票代码：VTRS）今日盘前股价大幅下跌7.34%，引起了市场的广泛关注。消息面上，公司近日宣布启动企业重组行动，预计将产生总额在7亿美元至8.5亿美元之间的税前费用。这一重大开支计划可能影响了投资者对公司短期财务表现的预期，从而导致了股价的下挫。公司表示，此次重组旨在优化运营结构，以提升长期竞争力，但市场对此短期成本的反应较为负面。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VTRS"],"gpt_icon":0},{"id":"1120213946","title":"Viatris纳西克工厂因二月火灾暂时停产，预计2026年4月起逐步恢复运营","url":"https://stock-news.laohu8.com/highlight/detail?id=1120213946","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120213946?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:24","pubTimestamp":1772108658,"startTime":"0","endTime":"0","summary":"全球医疗健康公司Viatris Inc.近日披露，其位于印度纳西克的制药生产基地因今年二月发生的火灾事故，目前已暂停生产活动。该公司表示，正全力推进设施修复与安全评估工作，预计最早将于2026年4月启动阶段性复产。\n此次停产主要影响该工厂特定生产线的运作，Viatris已启动业务连续性计划，通过全球供应链网络协调产能，以最大程度降低对产品供应的冲击。公司强调，将严格遵循当地监管要求，在确保安全合规的前提下有序恢复生产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2087621335.USD","BK4007","BK4585","LU1839511570.USD","VTRS","BK4588","BK4583"],"gpt_icon":0},{"id":"1113564178","title":"Viatris Inc.启动重组计划，预计税前费用总额介于7亿至8.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1113564178","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113564178?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:23","pubTimestamp":1772108631,"startTime":"0","endTime":"0","summary":"Viatris Inc.近日宣布启动企业重组行动，预计将产生总额在7亿美元至8.5亿美元之间的税前费用。这一举措旨在优化公司运营结构，提升长期竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1839511570.USD","LU2087621335.USD","VTRS","BK4583","BK4588","BK4007","BK4585"],"gpt_icon":0},{"id":"1187751292","title":"财报前瞻 ｜Viatris Inc.本季度营收预计降2.27%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1187751292","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187751292?lang=zh_cn&edition=full","pubTime":"2026-02-19 11:16","pubTimestamp":1771470989,"startTime":"0","endTime":"0","summary":"Viatris Inc.将于2026年02月26日发布最新季度财报，市场关注营收与利润承压的幅度及新品放量节奏对整体业绩的影响。公司目前的主营业务在整体口径上展现出韧性：上季度营收为37.60亿美元，同比增长0.23%，毛利率为39.84%，在价格压力背景下维持较为稳定的盈利质量。结合主营盘面的口径数据，上季度营收37.60亿美元、同比增长0.23%，在毛利率39.84%的配合下，显示存量品类与定价策略对现金创造能力仍具支撑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻 ｜Viatris Inc.本季度营收预计降2.27%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTRS"],"gpt_icon":0},{"id":"1135608545","title":"Viatris Inc. 心血管疾病创新产品组合扩容：首次推出心力衰竭治疗药物Inpefa®（Sotagliflozin）","url":"https://stock-news.laohu8.com/highlight/detail?id=1135608545","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135608545?lang=zh_cn&edition=full","pubTime":"2026-01-20 20:00","pubTimestamp":1768910436,"startTime":"0","endTime":"0","summary":"Viatris Inc. 正在通过其首次推出的心力衰竭治疗药物Inpefa®（Sotagliflozin），扩大其在心血管疾病领域的创新产品组合。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTRS","BK4007","BK4585","LU1839511570.USD","BK4588","LU2087621335.USD","BK4583"],"gpt_icon":0},{"id":"1119940118","title":"Viatris高管表示印多尔工厂初步修复工作基本完成，并与FDA就进展和重新检查的潜在时间进行了讨论 - 会议电话","url":"https://stock-news.laohu8.com/highlight/detail?id=1119940118","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119940118?lang=zh_cn&edition=full","pubTime":"2025-11-06 21:41","pubTimestamp":1762436495,"startTime":"0","endTime":"0","summary":"Viatris高管表示印多尔工厂初步修复工作基本完成，并与FDA就进展和重新检查的潜在时间进行了讨论 - 会议电话","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1839511570.USD","BK4583","VTRS","BK4585","BK4588","LU2087621335.USD"],"gpt_icon":0},{"id":"2575627899","title":"云顶新耀EVM14中美双获批，艾伯维新药报产，和美药业新药上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2575627899","media":"医药经济报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575627899?lang=zh_cn&edition=full","pubTime":"2025-10-14 18:11","pubTimestamp":1760436664,"startTime":"0","endTime":"0","summary":"云顶新耀EVM14中美双获批10月13日，专注于创新疗法的发现、临床开发、生产和商业化的生物制药公司云顶新耀宣布，其肿瘤相关抗原肿瘤疫苗EVM14的新药临床试验申请已获得NMPA的批准。此前，EVM14新药临床试验申请于2025年3月获FDA批准。此次获批的I期临床试验主要目的是观察EVM14的安全性和耐受性，次要目的是观察其疗效。在EVM14 I期临床试验探索的瘤种中，大多数患者会表达5个TAA之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014200833a6b8f5b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014200833a6b8f5b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1223082196.USD","CDE","BK4007","LU1223083913.SGD","BK4585","VTRS","BK4588","BK4017","LU0320765992.SGD","BK4568","AZN","LU2417539215.USD","LU1829250122.USD","LU0889565916.HKD","LU0109394709.USD","LU2236285917.USD","LU1223082519.USD","LU2462157665.USD","LU2456880835.USD"],"gpt_icon":0},{"id":"2517455736","title":"杰富瑞投资银行：维持Viatris(VTRS.US)评级，由买入调整至买入评级, 目标价由15.00美元调整至13.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517455736","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517455736?lang=zh_cn&edition=full","pubTime":"2025-03-08 01:22","pubTimestamp":1741368127,"startTime":"0","endTime":"0","summary":"杰富瑞投资银行：维持Viatris(VTRS.US)评级，由买入调整至买入评级, 目标价由15.00美元调整至13.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08012248604905.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["VTRS"],"gpt_icon":0},{"id":"2517167691","title":"晖致2024财年实现净利润-6.34亿美元，同比减少1259.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517167691","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517167691?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:01","pubTimestamp":1741276870,"startTime":"0","endTime":"0","summary":"3月7日，晖致公布财报，公告显示公司2024财年净利润为-6.34亿美元，同比减少1259.05%；其中营业收入为147.10亿美元，同比减少4.37%，每股基本收益为-0.53美元。通过强强联手，晖致医药有限公司成为世界上最大的仿制药制造商之一，为超过 165 个国家提供服务。虽然涵盖 10 多个主要治疗领域，但晖致医药有限公司已将皮肤科、眼科和胃肠科确定为未来创新的三个关键重点领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000136abeb8d1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000136abeb8d1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTRS"],"gpt_icon":0},{"id":"2516658827","title":"巴克莱：维持Viatris(VTRS.US)评级，由减持调整至减持评级, 目标价由12.00美元调整至9.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516658827","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516658827?lang=zh_cn&edition=full","pubTime":"2025-03-01 07:04","pubTimestamp":1740783850,"startTime":"0","endTime":"0","summary":"巴克莱：维持Viatris(VTRS.US)评级，由减持调整至减持评级, 目标价由12.00美元调整至9.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/01070448470449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["VTRS"],"gpt_icon":0},{"id":"1105655803","title":"异动解读 | Viatris公司财报低于预期加上FDA限制措施 股价盘中暴跌20%","url":"https://stock-news.laohu8.com/highlight/detail?id=1105655803","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105655803?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:49","pubTimestamp":1740667786,"startTime":"0","endTime":"0","summary":"Viatris Inc.公司股价今日盘中暴跌20.73%,引发市场广泛关注。公司股价大幅走低的主要原因来自以下两个方面:. 首先,Viatris公司2024年第四季度的财报数据出现了不尽理想的表现。此外,早些时候美国FDA针对Viatris在印度印多尔的工厂实施进口限制措施,也给公司今年的业务发展带来了不利影响。Viatris预计FDA的行动将减少公司2025年的收入约5亿美元,调整后核心利润也将减少约3.85亿美元。监管部门措施加剧了市场对公司增长前景的担忧,进一步推动了股价的暴跌走势。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VTRS"],"gpt_icon":0},{"id":"2514854013","title":"晖致盘中异动 股价大跌17.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514854013","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514854013?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:30","pubTimestamp":1740666604,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时30分，晖致股票出现异动，股价快速下跌17.62%。截至发稿，该股报9.26美元/股，成交量222.466万股，换手率0.19%，振幅0.00%。晖致股票所在的制药行业中，整体涨幅为0.00%。通过强强联手，晖致医药有限公司成为世界上最大的仿制药制造商之一，为超过 165 个国家提供服务。虽然涵盖 10 多个主要治疗领域，但晖致医药有限公司已将皮肤科、眼科和胃肠科确定为未来创新的三个关键重点领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022722300498950f96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022722300498950f96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU1839511570.USD","BK4007","VTRS","BK4583","LU2087621335.USD","BK4585"],"gpt_icon":0},{"id":"1139205945","title":"异动解读 | Viatris财报营收低于预期引发股价盘前大跌7.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139205945","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139205945?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:00","pubTimestamp":1740657635,"startTime":"0","endTime":"0","summary":"Viatris公司股价今日周四盘前交易大跌7.21%,主要受公司发布的2024年第四季度业绩报告拖累。\n\nViatris2024年第四季度财报显示,公司调整后每股收益0.54美元,低于市场预期的0.57美元;营收35.2亿美元,也未达到分析师预期的36.1亿美元。同时,财报显示公司同比去年的营收和每股收益均出现了下滑。\n\n公司业绩不达预期和同比下滑,令投资者对Viatris的盈利前景感到失望和担忧,引发了今日公司股票在盘前交易中大跌的行情。投资人将持续关注Viatris公司是否能在未来实现业绩复苏。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VTRS"],"gpt_icon":0},{"id":"1117219132","title":"Viatris 2024年第四季度调整后每股收益$0.54低于预期$0.57，销售额$35.2亿低于预期$36.1亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1117219132","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117219132?lang=zh_cn&edition=full","pubTime":"2025-02-27 19:58","pubTimestamp":1740657527,"startTime":"0","endTime":"0","summary":"Viatris  报告其季度每股收益为$0.54，比分析师一致预期的$0.57低5.26%。与去年同期的销售额$38.3亿相比，下降了8.13%。以上内容来自Benzinga Earnings专栏，原文如下：Viatris  reported quarterly earnings of $0.54 per share which missed the analyst consensus estimate of $0.57 by 5.26 percent. This is a 12.9 percent decrease over earnings of $0.62 per share from the same period last year.  The company reported quarterly sales of $3.52 billion which missed the analyst consensus estimate of $3.61 billion by 2.75 percent.  This is a 8.13 percent decrease over sa","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Viatris 2024年第四季度调整后每股收益$0.54低于预期$0.57，销售额$35.2亿低于预期$36.1亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTRS"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.viatris.com","stockEarnings":[{"period":"1week","weight":-0.0319},{"period":"1month","weight":-0.1608},{"period":"3month","weight":0.0915},{"period":"6month","weight":0.4078},{"period":"1year","weight":0.4366},{"period":"ytd","weight":0.0731}],"compareEarnings":[{"period":"1week","weight":-0.0263},{"period":"1month","weight":-0.0526},{"period":"3month","weight":-0.0539},{"period":"6month","weight":-0.0074},{"period":"1year","weight":0.1378},{"period":"ytd","weight":-0.0421}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viatris Inc.于2019年2月14日在特拉华州成立。该公司是一家全球性的医疗保健公司，该公司认为他们具有独特的定位，可以弥合仿制药和品牌之间的传统鸿沟，将两者的优点结合起来，以更全面地满足全球范围内的医疗保健需求。Viatris的使命是赋能世界各地的人们在生命的每个阶段都能过上更健康的生活，大规模地提供准入服务，目前每年为全球约10亿患者提供高质量的药物，并触及生命的所有时刻，从出生到生命的尽头，从急性病到慢性病。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.024969},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.073864},{"month":3,"riseRate":0,"avgChangeRate":-0.070577},{"month":4,"riseRate":0,"avgChangeRate":-0.038588},{"month":5,"riseRate":0.6,"avgChangeRate":0.054896},{"month":6,"riseRate":0.6,"avgChangeRate":-0.019914},{"month":7,"riseRate":0.4,"avgChangeRate":0.015693},{"month":8,"riseRate":0.8,"avgChangeRate":0.051},{"month":9,"riseRate":0,"avgChangeRate":-0.072997},{"month":10,"riseRate":0.4,"avgChangeRate":0.02449},{"month":11,"riseRate":0.8,"avgChangeRate":0.040541},{"month":12,"riseRate":0.833333,"avgChangeRate":0.086301}],"exchange":"NASDAQ","name":"Viatris Inc.","nameEN":"Viatris Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viatris Inc.(VTRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viatris Inc.(VTRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viatris Inc.,VTRS,Viatris Inc.股票,Viatris Inc.股票老虎,Viatris Inc.股票老虎国际,Viatris Inc.行情,Viatris Inc.股票行情,Viatris Inc.股价,Viatris Inc.股市,Viatris Inc.股票价格,Viatris Inc.股票交易,Viatris Inc.股票购买,Viatris Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viatris Inc.(VTRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viatris Inc.(VTRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}